

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/28, 9/30, 9/32, 9/34, 9/36, 9/38, 9/42</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/25323</b> <b>(43) International Publication Date:</b> 27 May 1999 (27.05.99)
<b>(21) International Application Number:</b> PCT/US98/24195 <b>(22) International Filing Date:</b> 13 November 1998 (13.11.98)  <b>(30) Priority Data:</b> 08/970,489 14 November 1997 (14.11.97) US  <b>(71) Applicant:</b> ANDRX PHARMACEUTICALS, INC. [US/US]; Suite 201, 4001 S.W. 47th Avenue, Fort Lauderdale, FL 33314 (US).  <b>(72) Inventors:</b> CHEN, Chih-Ming; 10680 S.W. 40th Manor, Davie, FL 33328 (US). CHOU, Joseph, C.H.; 5755 N.W. 54th Place, Coral Springs, FL 33067 (US). WENG, Timothy; 3 South Pine Island, Plantation, FL 33324 (US).  <b>(74) Agent:</b> COSTIGAN, James, V.; Hedman, Gibson & Costigan, P.C., 1185 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> OMEPRAZOLE FORMULATION  <b>(57) Abstract</b>  A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of (a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## OMEPRAZOLE FORMULATION

BACKGROUND OF THE INVENTION:

The present invention relates to a stable  
5 formulation of omeprazole. It is well known that  
omeprazole is sensitive to acidic conditions and the  
after contact with an acid, omeprazole will degrade and  
will not function in its intended manner. Initially,  
alkaline materials were added to a core of omeprazole  
10 and later an enteric coating was applied over the core  
to prevent the omeprazole from contacting the acidic pH  
conditions of the stomach. This approach is  
satisfactory if the product is administered within a  
short time after it is manufactured but if the product  
15 is stored under ambient conditions, the acidic residue  
of the enteric coating appears to degrade the  
omeprazole before it is administered to a patient. To  
solve this problem, the prior art has used a separate  
layer of a coating agent to coat a pellet core which  
20 contains omeprazole and an alkaline material which is  
thereafter coated with the enteric coating. This  
technique is described in U.S. 4,786,505.

This dual layer coating technique requires  
the application of two separate functional coating  
25 operations which increases the length of the  
manufacturing process and the cost of the product. The  
applicants have surprisingly discovered a coating  
system which avoids the need to use a coating layer to  
separate the omeprazole core from the enteric coating  
30 layer in an omeprazole dosage form. The separate  
coating system is based on the combined use of an  
enteric coating agent which is applied to pellet cores  
of omeprazole as a suspension in a suitable solvent.

SUMMARY OF THE INVENTION

The present invention provides a novel dosage form of omeprazole which consists essentially of:

- 5 (a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and  
(b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.

10 Accordingly, it is a primary object of this invention to provide a pharmaceutical dosage formulation of omeprazole which is stable upon prolonged storage, is stable when administered to a patient and is capable of providing the desired therapeutic effect.

15 It is also an object of this invention to provide a pharmaceutical dosage form of omeprazole which is bioequivalent to dosage forms of omeprazole which have an intermediate layer of an inert coating material.

20 It is also an object of this invention to provide a stable dosage form of omeprazole which may be produced without the need to provide an intermediate coating layer that separates the omeprazole containing core from the enteric coating layer.

25 These and other objects of the invention will become apparent from a review of the appended specification.

#### DETAILED DESCRIPTION OF THE INVENTION

30 The omeprazole formulation of the invention is preferably based on pellets having a core forming inert component which may comprise a starch or sugar sphere such as non-pareil sugar seeds having an average size of from 14 to 35 mesh, preferably about 18 to 20 mesh. The  
35 core forming inert component is coated with a formulation which comprises omeprazole, a surface active agent, a filler, an alkaline material and a binder,

which are collectively referred to hereafter as the drug layer composition. The core forming inert component is employed at 1:1 to 5:1 and preferably from 2:1 to 3:1 weight ratio to the drug layer composition.

5           The omeprazole may comprise from 20 to 70wt% and preferably 40 to 50wt% of the drug layer composition.

          The surface active agent may be any pharmaceutically acceptable, non-toxic surfactant.  
10   Suitable surface active agents include sodium lauryl sulfate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the like.

          The surface active agent may be present at a level of from 0.1 to 5wt% and preferably 0.25 to 2.5wt%  
15   based on the total weight of the drug layer composition.

          The alkaline material is selected from the group consisting of the sodium, potassium, calcium, magnesium and aluminum salts of phosphoric acid, carbonic acid, citric acid and aluminum/magnesium  
20   compounds such as  $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ ,  $(\text{Mg}_6\text{Al}_2(\text{OH}_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O}))$ ,  $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$  where n is a whole integer of 2 or more. In addition the alkaline material may be selected from the group consisting of antacid materials such as aluminum hydroxides, calcium  
25   hydroxides, magnesium hydroxides and magnesium oxide. The alkaline agent may be present at a level of 1 to 20wt% based on the total weight of the coating composition, depending on the relative strength of the alkaline material. If the preferred disodium phosphate  
30   alkaline agent is employed, a level of from 1 to 10wt% and preferably 4 to 7wt% based on the weight of the drug layer composition may be employed.

          The binder may be any pharmaceutically acceptable, non-toxic pharmaceutically acceptable  
35   binder.

          The binder is preferably a water soluble polymer of the group consisting of polyvinyl alcohol,

polyvinylpyrrolidone, methylcellulose, hydroxypropyl cellulose, hydroxymethyl cellulose and the like. A water soluble binder is preferred which is applied from an aqueous medium such as water at a level of from 0.1 to 5 wt% and preferably from 0.25 to 3wt% of binder based on the total weight of the drug layer composition.

A filler is added to the drug layer. Sugars such as lactose, dextrose, sucrose, maltose, microcrystalline cellulose and the like may be used as fillers in the pellet coating composition. The filler may comprise from 20 to 70wt% and preferably 40 to 50wt% based on the total weight of the drug layer composition.

The enteric coating agent may comprise an acid resisting material which resists acid up to a pH of above about 5.0 or higher which is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, Eudragit L (poly(methacrylic acid, methylmethacrylate), 1:1 ratio; MW (No. Av. 135,000 - USP Type A) or Eudragit S (poly(methacrylic acid, methylmethacrylate, 1:2 ratio MW (No. Av. 135,000 - USP Type B) and mixtures thereof.

The enteric coating agent may also include an inert processing aid in an amount from 10 to 80wt % and preferably 30 to 50wt% based on the total weight of the acid resisting component and the inert processing aid. The inert processing aids include finely divided forms of talc, silicon dioxide, magnesium stearate etc. Typical solvents which may be used to apply the acid resisting component-inert processing aid mixture include isopropyl alcohol, acetone, methylene chloride and the like. Generally the acid resistant component-inert processing aid mixture will be applied from a 5 to 20wt% of acid resisting component-inert processing aid mixture based on the total weight of the solvent and the acid resistant component-inert processing aid.

The cores are formed by spraying the non-

pareil seeds with an aqueous or non-aqueous suspension which contains the alkaline agent, the omeprazole, the surface active agent and the binder. The suspension medium may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like. When fluids such as water are employed, this will usually require a weight of fluid which is about seven times the weight of the dry components of the coating composition.

After the cores are dried, the cores are coated with the enteric coating agent. A color imparting agent may be added to the enteric coating agent mixture or a rapidly dissolving seal coat containing color may be coated over the enteric coating agent layer provided that the seal coat is compatible with and does not affect the dissolution of the enteric coating layer.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### EXAMPLE 1

Active pellets of omeprazole are formed by placing sugar spheres in a fluidized bed coater and spraying a suspension containing omeprazole onto the sugar spheres. The formulation for making the active pellets has the following composition:

povidone, USP (Plasdone K90)	4.5g
sodium lauryl sulfate, NF	10.6g
lactose anhydrous, NF	427.7g
disodium phosphate, NF	51.3g
omeprazole, USP (micronized)	427.7g
purified water, USP	3336.0g

The povidone, lactose anhydrous, disodium phosphate and the purified water are mixed with a mechanical mixer until the materials are dissolved. Then

the sodium lauryl sulfate is added to the mixture with gentle stirring to avoid the formation of excess foam until it dissolves completely. At that time the micronized omeprazole is added to the mixture and gentle stirring is continued until the micronized omeprazole is completely dispersed.

2500.0g of non-pareil sugar spheres (USPXII) (18/20 mesh) are placed in the fluidized bed coater and the suspension containing the omeprazole is coated at a product temperature of 35-45°C; an atomization pressure of 1.5 - 3.0 bar and a pump rate of 2-50ml/minute, starting with a slow rate of pumping to avoid agglomeration and increasing the rate of pumping consistent with the avoidance of the formation of agglomerates.

After coating is complete the pellets are dried at a temperature of 50°C until the loss on drying is less than 2.5wt%. The pellets are then screened through a #14 mesh screen and coated with the following enteric coating formulation:

hydroxypropylmethylcellulose phthalate, NF	258.1g
cetyl alcohol, NF	12.9g
talc, USP	129.0g
isopropyl alcohol, USP*	1663.0g
acetone, NF*	1663.0g
*evaporates during processing	

The hydroxypropylmethylcellulose phthalate and the cetyl alcohol are mixed with the isopropyl alcohol and the acetone with agitation until all of the materials are dissolved. The talc is dispersed with agitation in this solution. One kilogram of the active pellets are placed in a fluidized bed coater and all of the enteric coating mixture is applied using the coating conditions that were used to form the active pellets. The enteric coated pellets are then placed into No."2",



hard gelatin capsules containing pellets which are equivalent to 20mg of omeprazole.

The capsules were evaluated for stability as follows:

5 Dissolution stability:

After acid treatment for 2 hours in 500ml of 0.1N HCl solution at 37°C, the test samples were tested according to the USP XXII dissolution test (type 1, basket) at 100rpm, at 37° in phosphate buffer medium, USP XXII, at  
10 pH 6.8 to determine the percent of the drug dissolved versus time. The following results were obtained:

Time (min)	Percent Dissolved			
	<u>initial</u>	<u>40°C/75%RH/1mo</u>	<u>40°C/75%RH/2mo</u>	<u>40°C/75%RH/3mo</u>
15				
	10	87	76	95
	20	90	88	96
	30	90	86	95
	60	86	81	91
20				
				93
				95
				94
				89

Chemical and Acid Resistance Stability:

25 The acid resistance study was conducted by using the USP XXII dissolution test (type 1, basket), 100rpm, 37°C., in a aqueous solution of hydrochloric acid at pH 1.0. The following results were obtained:

30

		<u>initial</u>	<u>40°C/75%RH/1mo</u>	<u>40°C/75%RH/2mo</u>	<u>40°C/75%RH/3mo</u>
35	potency (% of LC)	101%	101%	100%	100%
	acid resistance (% of LC)	97%	100%	100%	99%
40					

A biostudy was carried out to compare the product of Example 1 with Prilosec brand of omeprazole (Ref. Mean) in humans. The following results were obtained in fasting humans:

	<u>Example 1</u>	<u>Mean</u>	<u>%CV</u>	<u>Ref. Mean</u>	<u>%CV</u>	<u>Geometric ratio</u>	<u>90%Confid.Interv. low.lim</u>	<u>upp. lim</u>
10	Cmax	134.50	61.46	133.46	60.11	0.964	72.47%	128.19%
	AUC 0~t	224.38	68.94	214.61	66.24	1.040	96.08%	112.63%
	AUC 0~8	230.87	65.78	220.54	64.76	1.052	97.42%	113.62%
15	Tmax	2.33	39.90	1.92	44.93	1.232		

All of the components which are used in the present invention are used in amounts which are effective for the intended purpose for which the component is employed.

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

## Claims:

1. A stable pharmaceutical composition of omeprazole for  
5 oral administration which consists essentially of:  
(a) a pellet comprising an inert core component, a  
therapeutically effective amount of omeprazole, a  
surface active agent, a filler, a pharmaceutically  
acceptable alkaline agent and a binder; and  
10 (b) a single layer of coating on said pellet which  
comprises a layer of an enteric coating agent.
2. A pharmaceutical composition of omeprazole as defined  
in claim 1 wherein the alkaline material is selected  
15 from the group consisting of the sodium, potassium,  
calcium, magnesium and aluminum salts of phosphoric  
acid, carbonic acid and citric acid.
3. A pharmaceutical composition of omeprazole as defined  
20 in claim 1 wherein the alkaline material is selected  
from the group consisting of aluminum hydroxides,  
calcium hydroxides, magnesium hydroxides and magnesium  
oxide.
- 25 4. A pharmaceutical composition of omeprazole as defined  
in claim 1 wherein the acid resistant component is  
selected from the group consisting of cellulose acetate  
phthalate, hydroxypropylmethyl cellulose phthalate,  
polyvinyl acetate phthalate,  
30 carboxymethylethylcellulose, co-polymerized methacrylic  
acid/methacrylic acid methyl esters.
5. A pharmaceutical composition of omeprazole as defined  
in claim 1 wherein the enteric coating agent also  
35 includes an inert processing aid.
6. A pharmaceutical composition of omeprazole as defined

in claim 1 wherein the enteric coating agent around the core includes from 10 to 80wt% of and inert processing aid.

5 7. A pharmaceutical composition of omeprazole as defined in claim 1 which includes a sodium lauryl sulfate as the surface active agent.

8. A pharmaceutical composition as defined in  
10 claim 1 wherein the core contains a non-pareil sugar seed.

9. A pelleted pharmaceutical dosage formulation which consists essentially of:

15 (a) a core comprising a non-pareil sugar seed coated with drug layer composition comprising omeprazole, a binder, an alkaline agent, a filler and a surface active agent; and

(b) an enteric coating agent around said core, said  
20 enteric coating comprising hydroxypropylmethyl cellulose phthalate and talc.

10. A pelleted pharmaceutical dosage formulation as defined in claim 9 wherein the alkaline agent is  
25 disodium phosphate.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/24195

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/28, 9/30, 9/32, 9/34, 9/36, 9/38, 9/42,

US CL : 424/474, 475, 476, 477, 479, 480, 481, 482

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/474, 475, 476, 477, 479, 480, 481, 482

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
NONE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,753,265 A (BERGSTRAND et al.) 19 MAY 1998, col. 6, lines 35-53, lines 50-58, col. 7, lines 10-27, col. 10, line 60 and col. 8, lines 30-65.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 JANUARY 1999

Date of mailing of the international search report

01 FEB 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL A. WILLIAMSON

Telephone No. (703) 308-1235